StockNews.AI
EWTX
StockNews.AI
146 days

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time

1. EWTX announces a webcast for EDG-7500 Phase 2 results on April 2, 2025. 2. The study focuses on hypertrophic cardiomyopathy (HCM) treatment advancements. 3. EDG-7500 is designed to improve heart function in diastolic dysfunction. 4. Edgewise Therapeutics specializes in novel muscle disease therapeutics. 5. Results may impact stock based on EWTX's drug efficacy perception.

5m saved
Insight
Article

FAQ

Why Bullish?

Strong drug candidates like EDG-7500 can increase investor confidence and stock value.

How important is it?

The Phase 2 results are critical for future developments and market confidence in EWTX.

Why Long Term?

Clinical trial outcomes often affect stock prices over extended periods, depending on results.

Related Companies

BMRNSRPTCRSP
, /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that members of the management team will hold a live webcast to discuss top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM 28-day trial in patients with obstructive or nonobstructive HCM on Wednesday, April 2, 2025, at 8:30 am ET.  The team is excited to be joined by two of the Company's CIRRUS-HCM investigators, who are world leaders in the care of patients with HCM.  An accompanying slide presentation will also be available. To register for the live webcast and replay, please visit the Edgewise events page. About EDG-7500 EDG-7500 is a novel oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with hypertrophic cardiomyopathy (HCM) and other diseases of diastolic dysfunction. To learn more about CIRRUS-HCM, visit clinicaltrials.gov, NCT06347159 (Phase 2).  About Edgewise Therapeutics                                                                                 Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission:  changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, X, Facebook and Instagram. This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release. Edgewise ContactsInvestors:Michael Carruthers, Chief Financial Officer[email protected]  Media:Maureen Franco, VP Corporate Communications[email protected] SOURCE Edgewise Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News